Andres R. Aguilar
Medical Oncology. Oncology Institute Dr. Rosell
Barcelona, CT, Spain
Barcelona, CT, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Phase Ib of repotrectinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 23, 2026
Assessing time to symptomatic progression, a patient-relevant efficacy endpoint, in the MARIPOSA study in non-small cell lung cancer.
Journal: European journal of cancer (Oxford, England : 1990)
Published: January 23, 2026
Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.
Journal: Targeted oncology
Published: September 02, 2025
Decoding B-cell Signatures of Complete Pathologic Response to Perioperative Chemoimmunotherapy in Non-Small Cell Lung Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: September 01, 2025
Energy Independence of the Collins Asymmetry in p^{↑}p Collisions.
Journal: Physical review letters
Published: July 23, 2025
Precision Measurement of Net-Proton-Number Fluctuations in Au+Au Collisions at RHIC.
Journal: Physical review letters
Published: March 26, 2025
Measurement of Two-Point Energy Correlators within Jets in p+p Collisions at sqrt[s]=200 GeV.
Journal: Physical review letters
Published: March 04, 2025
Efficacy and safety of lorlatinib in patients with ALK- and ROS1-rearranged metastatic non-small cell lung cancer treated within the compassionate use program in Spain.
Journal: Cancer treatment and research communications
Published: November 03, 2024
BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 19, 2024
Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions.
Journal: Expert opinion on investigational drugs
Published: February 19, 2024
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer.
Journal: Lung Cancer (Auckland, N.Z.)
Published: January 23, 2024
KRAS-mutant non-small cell lung cancer (NSCLC) therapy based on tepotinib and omeprazole combination.
Journal: Cell communication and signaling : CCS
Published: December 04, 2023
Last Updated: 09/26/2026